Larry Lo
- Immunology top 5%
- IL-33, ST2, and ILC Pathways 3
- Biotechnology top 10%
- Hematology top 10%
- Iron Metabolism and Disorders 3
- Erythropoietin and Anemia Treatment 3
- Nephrology top 10%
- Dialysis and Renal Disease Management 2
-
- Cell death mechanisms and regulation 2
-
- Management of metastatic bone disease 3
-
- Hemoglobinopathies and Related Disorders 2
-
- Spine and Intervertebral Disc Pathology 2
- Co-authors
- Matt DevalarajaMichael DavidsonPablo E. PérgolaDouglas KlingPaul M. RidkerDominic S. RajFlorian M.M. BaeresG. Kees Hovingh
- Cited by
- ImmunologyBiotechnologyHematology
- Journals
- International Journal of Radiation Oncology*Biology*Physics (2 papers)Radiotherapy and Oncology (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesNetherlandsItaly
In The Last Decade
Larry Lo
17 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 87
- Immunology 426
- Biotechnology 92
- Hematology 118
- Nephrology 61
- Molecular Biology 565
Countries citing papers authored by Larry Lo
This map shows the geographic impact of Larry Lo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry Lo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry Lo more than expected).
Fields of papers citing papers by Larry Lo
This network shows the impact of papers produced by Larry Lo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry Lo. The network helps show where Larry Lo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Larry Lo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialbreakdown → | 2021 | 433 |
| 2 | 2021 | 1 | |
| 3 | 2021 | 1 | |
| 4 | 2020 | 54 | |
| 5 | 2020 | 20 | |
| 6 | 2020 | 8 | |
| 7 | Abstract 13727: Effects of Ziltivekimab (ZILTI), a Novel Anti-Interleukin-6 Monoclonal Antibody, on Markers of Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease on Hemodialysis | 2019 | 3 |
| 8 | 2019 | 0 | |
| 9 | 2019 | 20 | |
| 10 | 2014 | 16 | |
| 11 | 2011 | 6 | |
| 12 | 2010 | 115 | |
| 13 | 2009 | 202 | |
| 14 | 2008 | 142 | |
| 15 | 2008 | 163 | |
| 16 | 2006 | 14 | |
| 17 | 2006 | 20 | |
| 18 | A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies. | 2005 | 6 |
About Larry Lo
Larry Lo is a scholar working on Hematology, Nephrology and Biotechnology, having authored 18 papers that have together received 1.2k indexed citations. Recurring topics across this work include IL-33, ST2, and ILC Pathways (3 papers), Iron Metabolism and Disorders (3 papers), Erythropoietin and Anemia Treatment (3 papers), Management of metastatic bone disease (3 papers), Dialysis and Renal Disease Management (2 papers), Cell death mechanisms and regulation (2 papers), Hemoglobinopathies and Related Disorders (2 papers) and Spine and Intervertebral Disc Pathology (2 papers). The work is most often cited by research in Immunology (426 citations), Biotechnology (92 citations) and Hematology (118 citations). Larry Lo has collaborated with scholars based in United States, Netherlands and Italy. Frequent co-authors include Matt Devalaraja, Michael Davidson, Pablo E. Pérgola, Douglas Kling, Paul M. Ridker, Dominic S. Raj, Florian M.M. Baeres, G. Kees Hovingh, Peter Libby and Mads D.M. Engelmann. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Radiotherapy and Oncology, Clinical Cancer Research, Journal of Clinical Medicine and Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.